ArticleCurrent pulmonology reports2015
The Challenge of Pulmonary Nontuberculous Mycobacterial Infection.
Article in Current pulmonology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Isolation of non-tuberculous mycobacteria among tuberculosis patients, a study from a tertiary care hospital in Lahore, Pakistan.BMC infectious diseases · 2021Article
- Mycobacterial Testing Trends, United States, 2009-2015Emerging infectious diseases · 2020Article
- Targeted Combination Antibiotic Therapy Induces Remission in Treatment-Naïve Crohn's Disease: A Case Series.Microorganisms · 2020Article
- HMGN2 regulates non-tuberculous mycobacteria survival via modulation of M1 macrophage polarization.Journal of cellular and molecular medicine · 2019Article
- Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target inAntimicrobial agents and chemotherapy · 2019Article
- Nontuberculous Mycobacteria, Botswana, 2011-2014.Emerging infectious diseases · 2019Article
- Medical management of bronchiectasis.Journal of thoracic disease · 2018Review
- Hospital-based antibiotic use in patients withERJ open research · 2018Article
- Genomic characterization of Nontuberculous Mycobacteria.Scientific reports · 2017Article
- The performance of interferon-gamma release assay in nontuberculous mycobacterial diseases: a retrospective study in China.BMC pulmonary medicine · 2016Article
- Differential Impairment of Interferon-Case reports in immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The incidence of nontuberculous mycobacterial (NTM) lung disease is increasing. Current treatment strategies are largely based on expert opinion. The lack of randomized clinical trials to inform treatment leave clinicians with many questions regarding the most effective and safe regimens. The risk-benefit ratio of therapy is often thought to favor observation given the chronic nature of the disease, multiple long-term antibiotics recommended for therapy, side effects associated with treatment, and perceived lack of efficacious therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.